These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 28255377)

  • 21. Therapeutic Plasma Exchange in Multiple Sclerosis Patients with Abolished Interferon-beta Bioavailability.
    Giedraitiene N; Kaubrys G; Kizlaitiene R; Bagdonaite L; Griskevicius L; Valceckiene V; Stoskus M
    Med Sci Monit; 2015 May; 21():1512-9. PubMed ID: 26009248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination.
    Rodriguez M; Karnes WE; Bartleson JD; Pineda AA
    Neurology; 1993 Jun; 43(6):1100-4. PubMed ID: 8170550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Changes in rheological properties of blood in multiple sclerosis and their correction].
    Karlov VA; Savin AA; Smertina LP; Redchits EG; Seleznev AN; Svetaĭlo LIu; Margosiuk NV; Stulin ID
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1990; 90(11):47-50. PubMed ID: 1706550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Use of therapeutic plasmapheresis in the exacerbation period of multiple sclerosis].
    Neretin VIa; Kir'iakova VA; Sapfirova VA; Ivanov MI; Volkova EK
    Sov Med; 1988; (2):86-9. PubMed ID: 3388103
    [No Abstract]   [Full Text] [Related]  

  • 25. Relapse of multiple sclerosis following acute allergic reactions to plasma during plasmapheresis.
    Wirguin I; Shinar E; Abramsky O
    J Neurol; 1989 Jan; 236(1):62-3. PubMed ID: 2915232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natural killer cell activity in patients with multiple sclerosis: interferon and plasmapheresis.
    Uchida A; Maida EM; Lenzhofer R; Micksche M
    Immunobiology; 1982 Feb; 160(5):392-402. PubMed ID: 6175561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [New therapeutic possibilities for disseminated sclerosis?].
    Wanscher B; Sørensen PS
    Ugeskr Laeger; 1994 Oct; 156(43):6353-8. PubMed ID: 7810008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Therapeutic plasmapheresis in multiple sclerosis (preliminary report)].
    Bokonjić R; Kantardzić D; Haracić M
    Neurologija; 1984; 32(1-2):3-11. PubMed ID: 6472573
    [No Abstract]   [Full Text] [Related]  

  • 29. Plasmapheresis in multiple sclerosis: preliminary findings.
    Dau PC; Petajan JH; Johnson KP; Panitch HS; Bornstein MB
    Neurology; 1980 Oct; 30(10):1023-8. PubMed ID: 6448360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased proliferation of blood mononuclear cells after plasmapheresis treatment of patients with demyelinating disease.
    Dau PC
    J Neuroimmunol; 1990 Nov; 30(1):15-21. PubMed ID: 2229403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Review. The status of plasmapheresis and apheresis].
    Schmitt E; Klinkmann H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(3):291-309. PubMed ID: 2428704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasmapheresis with immunosuppressive drug therapy in progressive multiple sclerosis. A pilot study.
    Khatri BO; Koethe SM; McQuillen MP
    Arch Neurol; 1984 Jul; 41(7):734-8. PubMed ID: 6234867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Plasmapheresis in multiple sclerosis].
    Fuchs S; Pogglitsch H; Ladurner G; Lechner H
    Wien Klin Wochenschr; 1984 Jan; 96(2):67-9. PubMed ID: 6710999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistence of antibrain antibodies in cerebrospinal fluid during plasmapheresis for multiple sclerosis.
    Ryberg B; Pirskanen R
    Br Med J (Clin Res Ed); 1985 Sep; 291(6499):850-1. PubMed ID: 2996688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs.
    Khatri BO; McQuillen MP; Harrington GJ; Schmoll D; Hoffmann RG
    Neurology; 1985 Mar; 35(3):312-9. PubMed ID: 3974889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurologic indications for therapeutic plasma exchange: an update.
    Gwathmey K; Balogun RA; Burns T
    J Clin Apher; 2011; 26(5):261-8. PubMed ID: 21915895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vestibular and ocular motor function prior to and after therapeutic apheresis with small plasmafilter in multiple sclerosis.
    Kolev OI; Kenarov P
    J Clin Apher; 2016 Oct; 31(5):470-2. PubMed ID: 26332668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A case report of double filtration plasmapheresis in an acute episode of multiple sclerosis.
    Ramunni A; De Robertis F; Brescia P; Saliani MT; Amoruso M; Prontera M; Dimonte E; Trojano M; Coratelli P
    Ther Apher Dial; 2008 Jun; 12(3):250-4. PubMed ID: 18503704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The dynamics of immunological indicators in the treatment of patients with multiple sclerosis with prednisolone combined with plasmapheresis].
    Neretin VIa; Gannushkina IV; Zhirnova IG; Sapfirova VA; Kir'iakov VA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1988; 88(2):17-21. PubMed ID: 3259769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lymphocytoplasmapheresis in multiple sclerosis: preliminary laboratory findings.
    Ghezzi A; Zaffaroni M; Caputo D; Guaschino R; Gasco P; Montanini R; Cazzullo CL
    Ital J Neurol Sci; 1985 Mar; 6(1):85-7. PubMed ID: 3997466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.